Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 2Unknown 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 1

Interventions

Cyclophosphamide 1492Cisplatin 1414Paclitaxel 1317Radiotherapy 1261Carboplatin 1250Gemcitabine 1215Docetaxel 1109Bevacizumab 1030Fluorouracil 894Doxorubicin 792Dexamethasone 748Rituximab 719Capecitabine 716Oxaliplatin 700pembrolizumab 680Etoposide 678Irinotecan 634Filgrastim 621Cytarabine 586Leucovorin 579Nivolumab 558Vincristine 515Prednisone 475Cetuximab 465Bortezomib 459Erlotinib Hydrochloride 456Trastuzumab 447Methotrexate 438Lenalidomide 427Pemetrexed 420

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Interventional × Iron × Clear all
NCT03993288 2021-07-12

Study to Test the Hypothesis of Non-inferior Efficacy and Safety of Ferrum LekĀ® (Iron (III) Hydroxide Polymaltosate), 100 mg Chewable Tablets (Lek d.d., Slovenia), as Compared With MALTOFERĀ® (Vifor S.A., Switzerland), in Subjects With Mild and Moderate Iron Deficiency Anemia.

Sandoz

Phase 3 Completed
267 enrolled 14 charts
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon ⚔